Key Facts:
VORANIGO® (vorasidenib) is available on the Pharmaceutical Benefits Scheme (PBS) for eligible patients living with Grade 2 IDH-mutant gliomai
This is the first new treatment option in more than 20 years to be approved and listed on the PBS for eligible Australians living with this rare, incurable brain cancer. 1
IDH-mutant glioma is the most common malignant primary brain tumour in adults under 50 years of age.ii
ADELAIDE, AUSTRALIA – 2 August 2026
Servier Australia welcomes today's Government announcement that Australians living with Grade 2 IDH-mutant astrocytoma or oligodendroglioma - a rare, incurable brain cancer – will have access to the first new treatment in more than 20 years. From 1 August VORANIGO® (vorasidenib) will be listed on the Pharmaceutical Benefits Scheme (PBS) for adults and adolescents aged 12 years and older with a susceptible IDH1 or IDH2 mutation who have not previously received systemic anticancer therapy or radiotherapy and meet the PBS eligibility criteria.1,iii
IDH-mutant glioma is the most common malignant primary brain tumour in adults under 50, affecting an estimated 3,230 Australians.2 Typically diagnosed between the ages of 20 and 45, the slow-growing but incurable disease can progress over many years, leaving people to face ongoing uncertainty, seizures, cognitive changes, physical disability and loss of independence while building careers, raising families and planning their futures.iv,v,vi
Until now, treatment options have largely relied on surgery, active monitoring and, where needed, radiotherapy or chemotherapy to slow disease progression.vii VORANIGO® (vorasidenib) is the first targeted treatment approved in Australia for Grade 2 IDH-mutant glioma. It is used to treat specific brain cancers with changes (mutations) in the IDH1 or IDH2 genes. These mutations cause abnormal proteins to form, leading to changes within cells that contribute to the growth of the cancer. VORANIGO® works by blocking the mutated proteins, helping to slow or stop the cancer from growing.3
Associate Professor Jim Whittle, Medical Oncologist at Peter MacCallum Cancer Centre and Co-Director of Research Strategy, The Brain Cancer Centre at WEHI states "For people living with IDH-mutant glioma, managing the disease involves making complex treatment decisions over many years. Caring for these patients often involves balancing long-term disease control with preserving neurological function and quality of life. Access to vorasidenib through the PBS provides clinicians with a targeted treatment option, adding another tool to the toolbox and supporting greater choice when discussing treatment options with patients".
The PBS listing has also been welcomed by the Australian Brain Tumour Collaborative (ABTC), which has worked alongside patients, clinicians, researchers and industry to improve awareness and outcomes for people living with IDH-mutant glioma.
"Behind every IDH-mutant glioma diagnosis is a person, a family and a future forever changed. For our community, today's PBS listing is a significant milestone after years of advocacy to improve access to new treatment options for Australians living with this rare brain cancer." said Craig Cardinal, Australian Brain Tumour Collaborative spokesperson
"Access to treatment is only one part of the journey. People living with brain cancer and their families also need coordinated multidisciplinary care, psychosocial support and practical services throughout every stage of their diagnosis." He added.
Mélanie Chamaux, General Manager, Servier Australia and New Zealand, said "We are incredibly proud of the PBS listing of VORANIGO®, which marks an important milestone for Australians living with IDH-mutant glioma. It reflects years of shared commitment from patients, families, clinicians, researchers, advocacy organisations and the Department of Health, Disability and Ageing, all united by a common goal: changing the trajectory of care for people living with IDH-mutant glioma. The listing represents a collective achievement of the healthcare system recognising therapeutic progress and the meaningful difference innovative medicines can make for patients, their families and the broader community.
We hope this milestone brings renewed confidence and optimism to those facing the challenges of this disease."
